You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 293 No. 9, March 2, 2005 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Nutritional and Metabolic Disorders
 •Lipids and Lipid Disorders
 •Otolaryngology/ Head & Neck Surgery
 •Endocrine Disease of Head & Neck
 •Endocrine Diseases
 •Thyroid/ Parathyroid Diseases
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Subclinical Thyroid Disease and Cardiovascular Disease—Reply

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In Reply: Dr Caraccio and colleagues1 raise important issues concerning risks of cardiovascular disease in subclinical hypothyroidism. Although a strong case can be made for recommending levothyroxine treatment for patients with serum TSH levels of more than 10 mIU/L, data supporting cardiovascular benefits of treatment when TSH level is minimally increased (>4.5 to ≤10 mIU/L) are weak and conflicting. The latter group constitutes about 80% of patients with subclinical hypothyroidism, representing millions of mainly older people, many of whom already have heart disease or have risk factors for heart disease. Studies of subclinical hypothyroidism are challenging because the magnitude of change and response to treatment of different parameters would likely be small and difficult to distinguish from controls. Also, large numbers of patients with serum TSH levels between 4.5 and 10 mIU/L are hard to find and maintain during lengthy treatment with levothyroxine.

In their randomized placebo-controlled trial, Caraccio . . . [Full Text of this Article]

Martin I. Surks, MD
msurks@westnet.com
Department of Medicine
Albert Einstein College of Medicine
Bronx, NY



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

Subclinical Thyroid Disease and Cardiovascular Disease
Nadia Caraccio, Angela Dardano, and Fabio Monzani
JAMA. 2005;293(9):1059-1060.
EXTRACT | FULL TEXT  

Subclinical Thyroid Disease: Scientific Review and Guidelines for Diagnosis and Management
Martin I. Surks, Eduardo Ortiz, Gilbert H. Daniels, Clark T. Sawin, Nananda F. Col, Rhoda H. Cobin, Jayne A. Franklyn, Jerome M. Hershman, Kenneth D. Burman, Margo A. Denke, Colum Gorman, Richard S. Cooper, and Neil J. Weissman
JAMA. 2004;291(2):228-238.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.